1. Group KDIGOCW. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter, Suppl 2013;3:1-150.
2. Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0158765.
3. Mills KT, Xu Y, Zhang W, et al. A systematic analysis of worldwide population- based data on the global burden of chronic kidney disease in 2010. Kidney Int 2015;88:950-7.
4. Imai E, Horio M, Watanabe T, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009;13:621-30.
5. 日本透析学会.わが国の慢性透析療法の現況（2018年12月31日現在）. 透析会誌 2019;52:679-754.
6. Kahn MR, Robbins MJ, Kim MC, Fuster V. Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol 2013;10:261-73.
7. Tanaka K, Watanabe T, Takeuchi A, et al. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int 2017;91:227-34.
8. Ishigami J, Matsushita K. Clinical epidemiology of infectious disease among patients with chronic kidney disease. Clin Exp Nephrol 2019;23:437-47.
9. Cheikh Hassan HI, Tang M, Djurdjev O, Langsford D, Sood MM, Levin A. Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortality. Kidney Int 2016;90:897-904.
10. 日台英雄兵.1．透析医療費の国際比較－第45回日本透析医学会パネルディスカッションより―. 透析会誌 2001;34:91-3.
11. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012;12:388-99.
12. Fishman JA. Infection in Organ Transplantation. Am J Transplant 2017;17:856- 79.
13. Gallagher MP, Kelly PJ, Jardine M, et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 2010;21:852-8.
14. Cherkas A, Holota S, Mdzinarashvili T, Gabbianelli R, Zarkovic N. Glucose as a Major Antioxidant: When, What for and Why It Fails? Antioxidants (Basel) 2020;9.
15. Kuehne A, Emmert H, Soehle J, et al. Acute Activation of Oxidative Pentose Phosphate Pathway as First-Line Response to Oxidative Stress in Human Skin Cells. Mol Cell 2015;59:359-71.
16. Bar-Even A, Flamholz A, Noor E, Milo R. Rethinking glycolysis: on the biochemical logic of metabolic pathways. Nat Chem Biol 2012;8:509-17.
17. Ying W. NAD+ and NADH in neuronal death. J Neuroimmune Pharmacol 2007;2:270-5.
18. Connell NJ, Houtkooper RH, Schrauwen P. NAD(+) metabolism as a target for metabolic health: have we found the silver bullet? Diabetologia 2019;62:888-99.
19. Martin A, Tegla CA, Cudrici CD, et al. Role of SIRT1 in autoimmune demyelination and neurodegeneration. Immunol Res 2015;61:187-97.
20. Imai S, Yoshino J. The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing. Diabetes Obes Metab 2013;15 Suppl 3:26-33.
21. Verdin E. NAD(+) in aging, metabolism, and neurodegeneration. Science 2015;350:1208-13.
22. Spencer RP, Bow TM. In Vitro Transport of Radiolabeled Vitamins by the Small Intestine. J Nucl Med 1964;5:251-8.
23. Grozio A, Mills KF, Yoshino J, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab 2019;1:47-57.
24. Gopal E, Fei YJ, Miyauchi S, Zhuang L, Prasad PD, Ganapathy V. Sodium- coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na/glucose co-transporter gene family. Biochem J 2005;388:309-16.
25. Kang HM, Ahn SH, Choi P, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med 2015;21:37-46.
26. Biasioli S, Feriani M, Bigi L, et al. Tricarboxylic acid cycle intermediates in chronic renal failure. Nephrol Dial Transplant 1987;2:313-5.
27. Hallan S, Afkarian M, Zelnick LR, et al. Metabolomics and Gene Expression Analysis Reveal Down-regulation of the Citric Acid (TCA) Cycle in Non-diabetic CKD Patients. EBioMedicine 2017;26:68-77.
28. Li M, Wang X, Aa J, et al. GC/TOFMS analysis of metabolites in serum and urine reveals metabolic perturbation of TCA cycle in db/db mice involved in diabetic nephropathy. Am J Physiol Renal Physiol 2013;304:F1317-24.
29. Oh GS, Kim HJ, Choi JH, et al. Pharmacological activation of NQO1 increases NAD(+) levels and attenuates cisplatin-mediated acute kidney injury in mice. Kidney Int 2014;85:547-60.
30. Guan Y, Wang SR, Huang XZ, et al. Nicotinamide Mononucleotide, an NAD(+) Precursor, Rescues Age-Associated Susceptibility to AKI in a Sirtuin 1-Dependent Manner. J Am Soc Nephrol 2017;28:2337-52.
31. Zhao W, Zhang L, Chen R, et al. SIRT3 Protects Against Acute Kidney Injury via AMPK/mTOR-Regulated Autophagy. Front Physiol 2018;9:1526.
32. Zheng M, Cai J, Liu Z, et al. Nicotinamide reduces renal interstitial fibrosis by suppressing tubular injury and inflammation. J Cell Mol Med 2019;23:3995-4004.
33. Klinkhammer BM, Djudjaj S, Kunter U, et al. Cellular and Molecular Mechanisms of Kidney Injury in 2,8-Dihydroxyadenine Nephropathy. J Am Soc Nephrol 2020;31:799-816.
34. Bollee G, Dollinger C, Boutaud L, et al. Phenotype and genotype characterization of adenine phosphoribosyltransferase deficiency. J Am Soc Nephrol 2010;21:679-88.
35. Diwan V, Brown L, Gobe GC. Adenine-induced chronic kidney disease in rats. Nephrology (Carlton) 2018;23:5-11.
36. Ali BH, Al-Salam S, Al Za'abi M, et al. New model for adenine-induced chronic renal failure in mice, and the effect of gum acacia treatment thereon: comparison with rats. J Pharmacol Toxicol Methods 2013;68:384-93.
37. Yoshino J, Baur JA, Imai SI. NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab 2018;27:513-28.
38. Wang X, Chaudhry MA, Nie Y, Xie Z, Shapiro JI, Liu J. A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy. J Vis Exp 2017.
39. Inouye K, Ueno I, Yokoyama S, Sakaki T. Development of a synchronous enzyme-reaction system for a highly sensitive enzyme immunoassay. J Biochem 2002;131:97-105.
40. Poyan Mehr A, Tran MT, Ralto KM, et al. De novo NAD(+) biosynthetic impairment in acute kidney injury in humans. Nat Med 2018;24:1351-9.
41. Muraoka H, Hasegawa K, Sakamaki Y, et al. Role of Nampt-Sirt6 Axis in Renal Proximal Tubules in Extracellular Matrix Deposition in Diabetic Nephropathy. Cell Rep 2019;27:199-212 e5.
42. Ralto KM, Rhee EP, Parikh SM. NAD(+) homeostasis in renal health and disease. Nat Rev Nephrol 2020;16:99-111.
43. Yakulov TA, Todkar AP, Slanchev K, et al. CXCL12 and MYC control energy metabolism to support adaptive responses after kidney injury. Nat Commun 2018;9:3660.
44. Yamamoto S, Yamamoto M, Nakamura J, et al. Spatiotemporal ATP Dynamics during AKI Predict Renal Prognosis. J Am Soc Nephrol 2020;31:2855-69.
45. Hershberger KA, Martin AS, Hirschey MD. Role of NAD(+) and mitochondrial sirtuins in cardiac and renal diseases. Nat Rev Nephrol 2017;13:213-25.
46. Ying W, Alano CC, Garnier P, Swanson RA. NAD+ as a metabolic link between DNA damage and cell death. J Neurosci Res 2005;79:216-23.
47. Mulay SR, Eberhard JN, Desai J, et al. Hyperoxaluria Requires TNF Receptors to Initiate Crystal Adhesion and Kidney Stone Disease. J Am Soc Nephrol 2017;28:761- 8.
48. Omote K, Gohda T, Murakoshi M, et al. Role of the TNF pathway in the progression of diabetic nephropathy in KK-A(y) mice. Am J Physiol Renal Physiol 2014;306:F1335-47.
49. Ye X, Luo T, Wang K, et al. Circulating TNF receptors 1 and 2 predict progression of diabetic kidney disease: A meta-analysis. Diabetes Metab Res Rev 2019;35:e3195.
50. Sonoda Y, Gohda T, Suzuki Y, et al. Circulating TNF receptors 1 and 2 are associated with the severity of renal interstitial fibrosis in IgA nephropathy. PLoS One 2015;10:e0122212.
51. Eto N, Miyata Y, Ohno H, Yamashita T. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 2005;20:1378-84.
52. Ramos-Martinez JI. The regulation of the pentose phosphate pathway: Remember Krebs. Arch Biochem Biophys 2017;614:50-2.
53. Cosmetic Ingredient Review Expert P. Final report of the safety assessment of niacinamide and niacin. Int J Toxicol 2005;24 Suppl 5:1-31.
論文の公開元へ
